TY - JOUR
T1 - Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline
AU - Sternberg, Zohara
AU - Podolsky, Rebecca
AU - Nir, Adam
AU - Yu, Jihnhee
AU - Nir, Raphael
AU - Halvorsen, Stanley W.
AU - Chadha, Kailash
AU - Quinn, Joseph F.
AU - Kaye, Jeffrey
AU - Kolb, Channa
N1 - Publisher Copyright:
© 2019
PY - 2019/5/15
Y1 - 2019/5/15
N2 - Background/aims: Prostate specific antigen (PSA) is regulated by steroid hormones, such as testosterone, the serum levels of which are altered in patients with Alzheimer's disease (AD).This pilot study compared serum levels of the free (f) PSA between AD, mild cognitive impairment (MCI), and control subjects, and evaluated the relationship between fPSA serum levels and cognitive assessment tests and neuroimaging data. In addition, in a subgroup of AD patients, we correlated fPSA serum levels with the existing data on serum levels of amyloid-beta (Aβ), and iron-related proteins, including hepcidin and ferritin. Methods: Frozen serum samples from the Oregon Tissue Bank were used to measure serum levels of fPSA using enzyme-linked immunosorbent assay. Results: fPSA serum levels calculated as median ± SD were higher in AD males (663.6 ± 821.0 pg/ml) compared to control males (152.0 ± 207.0 pg/ml), p = 0.003. A similar Pattern emerged when comparing MCI males (310.7 ± 367.0 pg/ml) to control males (P = 0.02). Correlation studies showed a significant association between fPSA and CDR (r = 0.56, P = 0.006) and CDR-SOB (r = 0.54, P = 0.009) in AD males. Conclusion: Additional studies in a larger cohort are required for determining whether fPSA can be used as biomarker of AD disease progression and whether it has the potential to identify male subjects at risk of AD dementia.
AB - Background/aims: Prostate specific antigen (PSA) is regulated by steroid hormones, such as testosterone, the serum levels of which are altered in patients with Alzheimer's disease (AD).This pilot study compared serum levels of the free (f) PSA between AD, mild cognitive impairment (MCI), and control subjects, and evaluated the relationship between fPSA serum levels and cognitive assessment tests and neuroimaging data. In addition, in a subgroup of AD patients, we correlated fPSA serum levels with the existing data on serum levels of amyloid-beta (Aβ), and iron-related proteins, including hepcidin and ferritin. Methods: Frozen serum samples from the Oregon Tissue Bank were used to measure serum levels of fPSA using enzyme-linked immunosorbent assay. Results: fPSA serum levels calculated as median ± SD were higher in AD males (663.6 ± 821.0 pg/ml) compared to control males (152.0 ± 207.0 pg/ml), p = 0.003. A similar Pattern emerged when comparing MCI males (310.7 ± 367.0 pg/ml) to control males (P = 0.02). Correlation studies showed a significant association between fPSA and CDR (r = 0.56, P = 0.006) and CDR-SOB (r = 0.54, P = 0.009) in AD males. Conclusion: Additional studies in a larger cohort are required for determining whether fPSA can be used as biomarker of AD disease progression and whether it has the potential to identify male subjects at risk of AD dementia.
KW - ACT
KW - Iron-related proteins
KW - Mild cognitive impairment
KW - Serum biomarker
UR - http://www.scopus.com/inward/record.url?scp=85064039354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064039354&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2019.04.006
DO - 10.1016/j.jns.2019.04.006
M3 - Article
C2 - 30981123
AN - SCOPUS:85064039354
SN - 0022-510X
VL - 400
SP - 188
EP - 193
JO - Journal of the neurological sciences
JF - Journal of the neurological sciences
ER -